A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®)

INTRODUCTION: Cancer patients receiving myelosuppressive chemotherapy are vulnerable to febrile neutropenia (FN) which contributes to poor treatment outcomes. The use of granulocyte colony-stimulating factors is administered to prevent chemotherapy-induced neutropenia. The introduction of biosimilar...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Gina, Zhang, Liying, Majeed, Habeeb, Razvi, Yasmeen, DeAngelis, Carlo, Lam, Emily, McKenzie, Erin, Wang, Katie, Pasetka, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669212/
https://www.ncbi.nlm.nih.gov/pubmed/33215563
http://dx.doi.org/10.1177/1078155220974085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669212/
https://www.ncbi.nlm.nih.gov/pubmed/33215563
http://dx.doi.org/10.1177/1078155220974085

Ejemplares similares